Challenges, Complexities, and Considerations in the Design and Interpretation of Late-Phase Oncology Trials
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Challenges, Complexities, and Considerations in the Design and Interpretation of Late-Phase Oncology Trials
Authors
Keywords
-
Journal
SEMINARS IN RADIATION ONCOLOGY
Volume 33, Issue 4, Pages 429-437
Publisher
Elsevier BV
Online
2023-09-07
DOI
10.1016/j.semradonc.2023.06.007
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- NRG/RTOG 1112: Randomized phase III study of sorafenib vs. stereotactic body radiation therapy (SBRT) followed by sorafenib in hepatocellular carcinoma (HCC).
- (2023) Laura A. Dawson et al. JOURNAL OF CLINICAL ONCOLOGY
- High-Dose Once-Daily Thoracic Radiotherapy in Limited-Stage Small-Cell Lung Cancer: CALGB 30610 (Alliance)/RTOG 0538
- (2023) Jeffrey Bogart et al. JOURNAL OF CLINICAL ONCOLOGY
- Using and Understanding Survival Statistics - or How We Learned to Stop Worrying and Love the Kaplan-Meier Estimate
- (2023) Søren M. Bentzen et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- The MaxCombo Test Severely Violates the Type I Error Rate
- (2023) Dominic Magirr et al. JAMA Oncology
- Assessment of Median and Mean Survival Time in Cancer Clinical Trials
- (2023) Ananya Das et al. JAMA Network Open
- Association between Prior Malignancy Exclusion Criteria and Age Disparities in Cancer Clinical Trials
- (2022) Roshal R. Patel et al. Cancers
- Understanding the Differences Between Bayesian and Frequentist Statistics
- (2022) Isabella Fornacon-Wood et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Post-protocol therapy and informative censoring in the CANDOR study
- (2022) Tomer Meirson et al. LANCET ONCOLOGY
- Incidence and impact of proportional hazards violations in phase 3 cancer clinical trials.
- (2022) Timothy Lin et al. JOURNAL OF CLINICAL ONCOLOGY
- Testing for Differences in Survival When Treatment Effects Are Persistent, Decaying, or Delayed
- (2022) John O'Quigley JOURNAL OF CLINICAL ONCOLOGY
- Log-Rank Test vs MaxCombo and Difference in Restricted Mean Survival Time Tests for Comparing Survival Under Nonproportional Hazards in Immuno-oncology Trials
- (2022) Pralay Mukhopadhyay et al. JAMA Oncology
- Interpreting the results of noninferiority trials—a review
- (2022) Jack Cuzick et al. BRITISH JOURNAL OF CANCER
- Handling Informative Premature Treatment or Study Discontinuation for Assessing Between-Group Differences in a Comparative Oncology Trial
- (2022) Bo Huang et al. JAMA Oncology
- The Bayesian Design of Adaptive Clinical Trials
- (2021) Alessandra Giovagnoli International Journal of Environmental Research and Public Health
- Detecting the Dark Matter of Unpublished Clinical Cancer Studies
- (2021) Dario Pasalic et al. MAYO CLINIC PROCEEDINGS
- Food and Drug Administration approvals in phase 3 Cancer clinical trials
- (2021) Joseph Abi Jaoude et al. BMC CANCER
- Informative censoring of surrogate end-point data in phase 3 oncology trials
- (2021) Shai Gilboa et al. EUROPEAN JOURNAL OF CANCER
- Bayesian interpretation of immunotherapy trials with dynamic treatment effects
- (2021) Eduardo Castañon et al. EUROPEAN JOURNAL OF CANCER
- The radiotherapy quality assurance gap among phase III cancer clinical trials
- (2021) Kelsey L. Corrigan et al. RADIOTHERAPY AND ONCOLOGY
- Assessment of Treatment Effects and Long-term Benefits in Immune Checkpoint Inhibitor Trials Using the Flexible Parametric Cure Model
- (2021) Thomas Filleron et al. JAMA Network Open
- Review of Clinical Equipoise: Examples from Oncology Trials
- (2021) Majd A. AlHamaly et al. Current Reviews in Clinical and Experimental Pharmacology
- Fulvestrant plus capivasertib for metastatic breast cancer
- (2020) Ethan B Ludmir et al. LANCET ONCOLOGY
- Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
- (2020) Richard S. Finn et al. NEW ENGLAND JOURNAL OF MEDICINE
- FDA Acceptance of Surrogate End Points for Cancer Drug Approval: 1992-2019
- (2020) Emerson Y. Chen et al. JAMA Internal Medicine
- Precision oncology: the intention-to-treat analysis fallacy
- (2020) Jason K. Sicklick et al. EUROPEAN JOURNAL OF CANCER
- Progression-free survival is a suboptimal predictor for overall survival among metastatic solid tumour clinical trials
- (2020) Dario Pasalic et al. EUROPEAN JOURNAL OF CANCER
- Performance Status Restriction in Phase III Cancer Clinical Trials
- (2020) Joseph Abi Jaoude et al. Journal of the National Comprehensive Cancer Network
- Progression-free survival in the ICON8 trial
- (2020) Ethan B Ludmir et al. LANCET
- Trial Sponsorship and Time to Reporting for Phase 3 Randomized Cancer Clinical Trials
- (2020) Timothy A. Lin et al. Cancers
- Estimation of Study Time Reduction Using Surrogate End Points Rather Than Overall Survival in Oncology Clinical Trials
- (2019) Emerson Y. Chen et al. JAMA Internal Medicine
- Analysis of Control Arm Quality in Randomized Clinical Trials Leading to Anticancer Drug Approval by the US Food and Drug Administration
- (2019) Talal Hilal et al. JAMA Oncology
- Deviation from the Proportional Hazards Assumption in Randomized Phase 3 Clinical Trials in Oncology: Prevalence, Associated Factors and Implications
- (2019) Rifaquat M Rahman et al. CLINICAL CANCER RESEARCH
- Sex-Based Disparities Among Cancer Clinical Trial Participants
- (2019) Ethan B Ludmir et al. JNCI-Journal of the National Cancer Institute
- Factors Associated With Age Disparities Among Cancer Clinical Trial Participants
- (2019) Ethan B. Ludmir et al. JAMA Oncology
- Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial
- (2019) Anders Widmark et al. LANCET
- Adaptive platform trials: definition, design, conduct and reporting considerations
- (2019) NATURE REVIEWS DRUG DISCOVERY
- Quantifying the benefit of non-small-cell lung cancer immunotherapy
- (2019) Ethan B Ludmir et al. LANCET
- Current management of limited-stage SCLC and CONVERT trial impact: Results of the EORTC Lung Cancer Group survey
- (2019) Antonin Levy et al. LUNG CANCER
- Incidence and correlates of HIV exclusion criteria in cancer clinical trials
- (2019) Ethan B. Ludmir et al. INTERNATIONAL JOURNAL OF CANCER
- Methods for Accommodating Nonproportional Hazards in Clinical Trials: Ready for the Primary Analysis?
- (2019) Boris Freidlin et al. JOURNAL OF CLINICAL ONCOLOGY
- When is crossover desirable in cancer drug trials and when is it problematic?
- (2018) A Haslam et al. ANNALS OF ONCOLOGY
- The Current Status of Drug Discovery and Development as Originated in US Academia: The Influence of Industrial and Academic Collaboration on Drug Discovery and Development
- (2018) Tohru Takebe et al. CTS-Clinical and Translational Science
- Hazards of Hazard Ratios — Deviations from Model Assumptions in Immunotherapy
- (2018) Brian M. Alexander et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
- (2018) Ghassan K. Abou-Alfa et al. NEW ENGLAND JOURNAL OF MEDICINE
- Do Surrogate Endpoints Better Correlate with Overall Survival in Studies That Did Not Allow for Crossover or Reported Balanced Postprogression Treatments? An Application in Advanced Non–Small Cell Lung Cancer
- (2018) Mahmoud Hashim et al. VALUE IN HEALTH
- Systematic bias between blinded independent central review and local assessment: literature review and analyses of 76 phase III randomised controlled trials in 45 688 patients with advanced solid tumour
- (2018) Jianrong Zhang et al. BMJ Open
- Association between progression-free survival and patients’ quality of life in cancer clinical trials
- (2018) Thomas J. Hwang et al. INTERNATIONAL JOURNAL OF CANCER
- Bayesian Analysis: Using Prior Information to Interpret the Results of Clinical Trials
- (2017) Melanie Quintana et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial
- (2017) Corinne Faivre-Finn et al. LANCET ONCOLOGY
- iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
- (2017) Lesley Seymour et al. LANCET ONCOLOGY
- Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After Approval
- (2017) Vinay Prasad et al. JAMA Internal Medicine
- The reproducibility of research and the misinterpretation of p -values
- (2017) David Colquhoun Royal Society Open Science
- Interpretability of Cancer Clinical Trial Results Using Restricted Mean Survival Time as an Alternative to the Hazard Ratio
- (2017) Kyongsun Pak et al. JAMA Oncology
- Observer variability in RECIST-based tumour burden measurements: a meta-analysis
- (2016) Soon Ho Yoon et al. EUROPEAN JOURNAL OF CANCER
- Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial
- (2016) David Dearnaley et al. LANCET ONCOLOGY
- Strength of Validation for Surrogate End Points Used in the US Food and Drug Administration's Approval of Oncology Drugs
- (2016) Chul Kim et al. MAYO CLINIC PROCEEDINGS
- The STAMPEDE trial: paradigm-changing data through innovative trial design
- (2016) Bradley C. Carthon et al. Translational Cancer Research
- Alternatives to Hazard Ratios for Comparing the Efficacy or Safety of Therapies in Noninferiority Studies
- (2015) Hajime Uno et al. ANNALS OF INTERNAL MEDICINE
- A versatile test for equality of two survival functions based on weighted differences of Kaplan-Meier curves
- (2015) Hajime Uno et al. STATISTICS IN MEDICINE
- Moving Beyond the Hazard Ratio in Quantifying the Between-Group Difference in Survival Analysis
- (2014) Hajime Uno et al. JOURNAL OF CLINICAL ONCOLOGY
- Scientific method: Statistical errors
- (2014) Regina Nuzzo NATURE
- Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome
- (2013) Patrick Royston et al. BMC Medical Research Methodology
- The Clinical Viewpoint: Definitions, Limitations of RECIST, Practical Considerations of Measurement
- (2013) L. C. Villaruz et al. CLINICAL CANCER RESEARCH
- Utilizing the integrated difference of two survival functions to quantify the treatment contrast for designing, monitoring, and analyzing a comparative clinical study
- (2012) Lihui Zhao et al. Clinical Trials
- RTOG 0529: A Phase 2 Evaluation of Dose-Painted Intensity Modulated Radiation Therapy in Combination With 5-Fluorouracil and Mitomycin-C for the Reduction of Acute Morbidity in Carcinoma of the Anal Canal
- (2012) Lisa A. Kachnic et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Design Issues in Randomized Phase II/III Trials
- (2012) Edward L. Korn et al. JOURNAL OF CLINICAL ONCOLOGY
- Progression-Free Survival: Meaningful or Simply Measurable?
- (2012) Christopher M. Booth et al. JOURNAL OF CLINICAL ONCOLOGY
- Accelerated Approval of Oncology Products: The Food and Drug Administration Experience
- (2011) John R. Johnson et al. JNCI-Journal of the National Cancer Institute
- Long-Term Results of Hypofractionated Radiation Therapy for Breast Cancer
- (2010) Timothy J. Whelan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Bayesian statistics in oncology
- (2009) Michel Adamina et al. CANCER
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
- Fluorouracil, Mitomycin, and Radiotherapy vs Fluorouracil, Cisplatin, and Radiotherapy for Carcinoma of the Anal Canal
- (2008) Jaffer A. Ajani JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Blinded Independent Central Review of Progression-Free Survival in Phase III Clinical Trials: Important Design Element or Unnecessary Expense?
- (2008) Lori E. Dodd et al. JOURNAL OF CLINICAL ONCOLOGY
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Dirty Dozen: Twelve P-Value Misconceptions
- (2008) Steven Goodman SEMINARS IN HEMATOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started